<DOC>
	<DOCNO>NCT00278213</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , cyclophosphamide , mitoxantrone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Combination chemotherapy follow alemtuzumab may effective treat chronic lymphocytic leukemia prolymphocytic leukemia . PURPOSE : This phase II trial study well give combination chemotherapy follow alemtuzumab work treat patient T-cell chronic lymphocytic leukemia prolymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Alemtuzumab Treating Patients With Chronic Lymphocytic Leukemia Prolymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine number severe adverse event life-threatening infection patient T-cell chronic lymphocytic leukemia T-cell prolymphocytic leukemia treat induction chemotherapy comprise fludarabine , cyclophosphamide , mitoxantrone hydrochloride follow consolidation therapy comprise alemtuzumab . - Determine remission rate patient treat regimen . Secondary - Determine overall progression-free survival patient treat regimen . - Determine quality remission patient treat regimen . OUTLINE : This multicenter study . Patients receive induction chemotherapy comprise fludarabine IV cyclophosphamide IV 3 day mitoxantrone hydrochloride IV 1 day . Treatment repeat every 28 day 4 course . Patients receive consolidation therapy comprise alemtuzumab IV 3 time week 1 weekly 11 week . PROJECTED ACCRUAL : A total 17 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Tcell chronic lymphocytic leukemia ( TCLL ) Tcell prolymphocytic leukemia ( TPLL ) Previously untreated disease OR patient may receive 2 therapy PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 6 month No severe organ dysfunction No concurrent previous neoplasm No autoimmune hemolytic anemia thrombocytopenia PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior fludarabine , mitoxantrone hydrochloride , cyclophosphamide , alemtuzumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
</DOC>